Compare BridgeBio Pharma Inc (BBIO) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vital Farms Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Vital Farms Inc trades at $11.57 (market cap $483.84M). The key difference: BridgeBio Pharma Inc is far larger — about 34.3× Vital Farms Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | VITL | |
|---|---|---|
Market Cap | $16.61B | $483.84M |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $52.41 |
52-Week Low | $47.29 | $8.28 |
Enterprise Value | $18.16B | $570.85M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Vital Farms (VITL) trades at $12.24, down 2.16% amid bearish technical signals and challenging Q2 2026 results with a net loss of $0.47 per share. Revenue declined 10.1% year-over-year to $166 million due to industry oversupply and competitive pressures. The company secured $125 million in term loan financing in August 2026 to support operations. Analyst consensus remains positive with a $13.00 price target and 56% buy ratings, though profitability metrics show significant compression with net income margin at 0.02%.
The stock faces near-term headwinds from operational challenges but maintains analyst support. Investment opportunity exists if the company can navigate industry oversupply and restore profitability. Key risks include persistent margin pressure, competitive pricing gaps, and execution of the new financing strategy. The current valuation at 11.77 P/E appears reasonable if earnings recovery materializes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
